EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).

Ablation Antiarrhythmic drugs Anticoagulants Arrhythmias Atrial fibrillation Cachexia Cardiac resynchronization therapy Cardiac resynchronization therapy-defibrillator Cognitive impairment Consensus document Elderly European Heart Rhythm Association Frailty Frailty assessment Frailty domains Frailty syndrome Heart failure Implantable cardioverter-defibrillator Pacemaker Position paper Pre-frailty state Stroke Ventricular tachycardia

Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
15 04 2023
Historique:
received: 22 06 2022
accepted: 27 06 2022
medline: 5 5 2023
pubmed: 17 4 2023
entrez: 16 4 2023
Statut: ppublish

Résumé

There is an increasing proportion of the general population surviving to old age with significant chronic disease, multi-morbidity, and disability. The prevalence of pre-frail state and frailty syndrome increases exponentially with advancing age and is associated with greater morbidity, disability, hospitalization, institutionalization, mortality, and health care resource use. Frailty represents a global problem, making early identification, evaluation, and treatment to prevent the cascade of events leading from functional decline to disability and death, one of the challenges of geriatric and general medicine. Cardiac arrhythmias are common in advancing age, chronic illness, and frailty and include a broad spectrum of rhythm and conduction abnormalities. However, no systematic studies or recommendations on the management of arrhythmias are available specifically for the elderly and frail population, and the uptake of many effective antiarrhythmic therapies in these patients remains the slowest. This European Heart Rhythm Association (EHRA) consensus document focuses on the biology of frailty, common comorbidities, and methods of assessing frailty, in respect to a specific issue of arrhythmias and conduction disease, provide evidence base advice on the management of arrhythmias in patients with frailty syndrome, and identifies knowledge gaps and directions for future research.

Identifiants

pubmed: 37061780
pii: 7036349
doi: 10.1093/europace/euac123
pmc: PMC10105859
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1249-1276

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.

Déclaration de conflit d'intérêts

Conflicts of interest: The authors have provided declaration of interest information for all relationships that might be perceived as real or potential sources of conflicts of interest. The full disclosures can be viewed in the supplementary material for this article.

Auteurs

Irina Savelieva (I)

Cardiovascular Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St George's University of London, London, UK.

Stefano Fumagalli (S)

Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, University of Florence and AOU Careggi, Florence, Italy.

Rose Anne Kenny (RA)

Mercer's Institute for Successful Ageing, Department of Medical Gerontology, St James's Hospital, Dublin, Ireland.

Stefan Anker (S)

Department of Cardiology (CVK), Germany.
Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Germany.
German Centre for Cardiovascular Research (DZHK) partner site Berlin, Germany.
Charité Universitätsmedizin Berlin, Germany.

Athanase Benetos (A)

Department of Geriatric Medicine CHRU de Nancy and INSERM U1116, Université de Lorraine, Nancy, France.

Giuseppe Boriani (G)

Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy.

Jared Bunch (J)

(HRS representative): Intermountain Medical Center, Cardiology Department, Salt Lake City, Utah, USA.
Stanford University, Department of Internal Medicine, Palo Alto, CA, USA.

Nikolaos Dagres (N)

Heart Center Leipzig, Department of Electrophysiology, Leipzig, Germany.

Sergio Dubner (S)

(LAHRS representative): Clinica Suizo Argentina, Cardiology Department, Buenos Aires Capital Federal, Argentina.

Laurent Fauchier (L)

Centre Hospitalier Universitaire Trousseau et Université François Rabelais, Tours, France.

Luigi Ferrucci (L)

National Institute on Aging, MD, USA.

Carsten Israel (C)

Evangelisches Krankenhaus Bielefeld GmbH, Bielefeld, Germany.

Hooman Kamel (H)

Department of Neurology, Weill Cornell Medical College, New York, NY, USA.

Deirdre A Lane (DA)

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom.
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom.
Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Gregory Y H Lip (GYH)

Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom.
Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom.
Liverpool Heart and Chest Hospital, Liverpool, United Kingdom.
Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.

Niccolò Marchionni (N)

Department of Experimental and Clinical Medicine, General Cardiology Division, University of Florence and AOU Careggi, Florence, Italy.

Israel Obel (I)

(CASSA representative): Milpark Hospital, Cardiology Unit, Johannesburg, South Africa.

Ken Okumura (K)

(APHRS representative): Saiseikai Kumamoto Hospital, Kumamoto, Japan.

Brian Olshansky (B)

University of Iowa Hospitals and Clinics, Iowa City Iowa, USA.
Covenant Hospital, Waterloo, Iowa, USA.
Mercy Hospital Mason City, Iowa, USA.

Tatjana Potpara (T)

School of Medicine, Belgrade University, Serbia.
Cardiology Clinic, Clinical Center of Serbia, Serbia.

Martin K Stiles (MK)

(APHRS representative): Waikato Clinical School, University of Auckland and Waikato Hospital, Hamilton, New Zealand.

Juan Tamargo (J)

Department of Pharmacology, School of Medicine, CIBERCV, Universidad Complutense, Madrid, Spain.

Andrea Ungar (A)

Department of Experimental and Clinical Medicine, Geriatric Intensive Care Unit and Geriatric Arrhythmia Unit, University of Florence and AOU Careggi, Florence, Italy.

Jedrzej Kosiuk (J)

Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany.

Torben Bjerregaard Larsen (TB)

Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.

Borislav Dinov (B)

Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany.

Heidi Estner (H)

Klinikum d. Universität München Campus, München, Germany.

Rodrigue Garcia (R)

Chu De Poitiers, Service De Cardiologie, Poitiers, France.

Francisco Manuel Moscoso Costa (FM)

Cardiology Department, Hospital Santa Cruz, Lisbon, Portugal.

Rachel Lampert (R)

Yale University School of Medicine, Section of Cardiovascular Medicine, CT, USA.

Yenn-Jiang Lin (YJ)

Taipei Veterans General Hospital, Cardiology Division, Taipei, Taiwan.

Ashley Chin (A)

UCT Private Academic Hospital, Cape Town, South Africa.

Heliodoro Antonio Rodriguez (HA)

Centro Medico Docente la Trinidad, Cardiology Unit, Caracas, Miranda, Venezuela.

Timo Strandberg (T)

Department of Health Sciences/Geriatrics, University of Oulu, Oulu, Finland.

Tomasz Grodzicki (T)

Jagiellonian University Medical College, Cracow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH